No price
PreclinicalSmall molecule
No price is one of 12 small molecule programs targeting Cholecystitis. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Cholecystitis
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Zofran
NovartisApproved
IC-Green
CCHX Technologies Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Avelox
BayerPhase 3
Amoxicillin-Clavulanic Acid
TevaPhase 3
Piperacillin-Tazobactam Combination Product
TThe University of Queensland
Phase 3
Amoxicillin-Clavulanic
AAssistance Publique - Hôpitaux de Paris
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cholecystitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for No price. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHadassah Medical Organization